Lupin Digital Health Emerges as India’s Most Resilient Digital Therapeutics Player with Clinically Proven Cardiac Platform LYFE

While several digital therapeutics (DTx) startups have folded or been acquired under pressure, Lupin Digital Health has quietly built one of India’s most resilient platforms — backed by clinical evidence, hospital partnerships, and physician trust. Launched in 2022, Lupin’s flagship platform LYFE is India’s first CDSCO-approved Class C software medical device for cardiac care. Unlike many competitors that rushed to market, Lupin focused on clinical validation, conducting trials and publishing more than 15 peer-reviewed studies demonstrating statistically significant improvements in blood pressure, cholesterol, and hospital readmissions. “You can’t just say, ‘trust me, bro.’ You have to generate evidence,” said Sidharth Srinivasan, CEO of Lupin Digital Health. “Doctors trust us because we’ve earned it — not because we’re backed by Lupin.” Currently, LYFE is prescribed by over 1,000 cardiologists and deployed across 60+ hospitals in India. Expanding its footprint, the company recently launched VITALYFE, an AI-powered cardiometabolic wellness platform designed for India’s workforce, featuring heart age tracking, photo-based nutrition logging, and camera-guided exercise. While large pharma players like Cipla and Dr. Reddy’s have struggled to scale in DTx, Lupin Digital Health has maintained positive unit economics, driven by physician prescriptions and insurer partnerships to reduce lifestyle-related claims. “We’re creating a market where none existed,” Srinivasan added. “It’s tough, but we’ve cracked the model — and we’re here to stay.” Hashtags: #LupinDigitalHealth #DigitalTherapeutics #HealthTech #LYFE #VITALYFE #CardiacCare #AIinHealthcare #MedTechIndia #HealthcareInnovation #ClinicalEvidence